Real world efficacy of 1st-line nivolumab plus ipilimumab and its practical predictive biomarkers in advanced renal cell carcinoma: first analysis from RENOIR study [KCSG GU22-13]
구분
국외
국가
스페인
컨퍼런스명
2024 ESMO congress
발표 제목
Real world efficacy of 1st-line nivolumab plus ipilimumab and its practical predictive biomarkers in advanced renal cell carcinoma: first analysis from RENOIR study [KCSG GU22-13]